# Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)

Source: https://onco.cc/trials/nct02432846/  
OnCo record `nct02432846` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ilixadencel run by Mendus, completed.

## Summary

Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) is a phase 2 interventional study registered as NCT02432846 by Mendus, with 88 participants enrolled, started 2015-04. Conditions recorded: Renal Cell Carcinoma, Metastatic. Interventions recorded: Intuvax (INN: ilixadencel) and Sunitinib.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02432846
- Phase: 2
- Setting: An Open-label, Randomized, Controlled, Multicenter, Phase II Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy, Compared to Sunitinib Post-nephrectomy in Metastatic Renal Cell Carcinoma Patients
- Sponsor: Mendus
- Enrolled: 88

## Sources

- ClinicalTrials.gov NCT02432846: https://clinicaltrials.gov/study/NCT02432846

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Ilixadencel](https://onco.cc/drugs/ilixadencel/)
- companies: [Mendus](https://onco.cc/companies/mendus/)

---
JSON: https://onco.cc/api/v1/entities/nct02432846.json